Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued on Monday,Benzinga reports. They presently have a $46.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 7.96% from the company’s current price.

DNTH has been the subject of a number of other reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Guggenheim raised their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Stifel Nicolaus upped their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Finally, Truist Financial assumed coverage on Dianthus Therapeutics in a research report on Tuesday, October 14th. They set a “buy” rating and a $56.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.43.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $42.61 on Monday. The business’s fifty day moving average is $39.25 and its two-hundred day moving average is $30.16. The firm has a market cap of $1.83 billion, a P/E ratio of -12.24 and a beta of 1.56. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $45.46.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 216,538 shares of company stock worth $8,283,175. 16.56% of the stock is currently owned by company insiders.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Parkside Financial Bank & Trust raised its position in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 540 shares during the period. ADAR1 Capital Management LLC increased its stake in Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock valued at $332,000 after purchasing an additional 602 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock worth $3,049,000 after purchasing an additional 1,081 shares during the period. Finally, Bessemer Group Inc. boosted its position in shares of Dianthus Therapeutics by 7.8% during the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock worth $635,000 after purchasing an additional 1,170 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.